[{"address1": "Gustavslundsv\u00e4gen 42", "address2": "5th Floor", "city": "Bromma", "zip": "167 51", "country": "Sweden", "phone": "46 8 52 23 07 00", "fax": "46 87 35 20 29", "website": "https://www.mobergpharma.se", "industry": "Drug Manufacturers\u2014Specialty & Generic", "sector": "Healthcare", "longBusinessSummary": "Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products primarily in Sweden. It develops MOB-015, which has completed Phase III clinical trial for the treatment of nail fungus. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. Moberg Pharma AB (publ) was incorporated in 2006 and is headquartered in Bromma, Sweden.", "fullTimeEmployees": 9, "companyOfficers": [{"maxAge": 1, "name": "Ms. Anna  Ljung BA, M.Sc.", "age": 43, "title": "Chief Executive Officer", "yearBorn": 1980, "fiscalYear": 2023, "totalPay": 2930000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Marie  Moberg", "title": "Co-Founder", "fiscalYear": 2023, "totalPay": 193701, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mark  Beveridge", "age": 45, "title": "Vice President of Finance", "yearBorn": 1978, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Christina  Erixon", "age": 53, "title": "Head of Pharmaceutical Development & Operations", "yearBorn": 1970, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Gunilla  Wengstr\u00f6m", "title": "Senior Director of Sales & Marketing", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Anders  Broijersen M.D., Ph.D.", "age": 59, "title": "Chief Medical Officer", "yearBorn": 1964, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Robert  Ehrl", "age": 56, "title": "Head of Supply", "yearBorn": 1967, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 8, "compensationRisk": 7, "shareHolderRightsRisk": 4, "overallRisk": 8, "governanceEpochDate": 1717200000, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.25, "open": 2.32, "dayLow": 2.28, "dayHigh": 2.37, "regularMarketPreviousClose": 2.25, "regularMarketOpen": 2.32, "regularMarketDayLow": 2.28, "regularMarketDayHigh": 2.37, "exDividendDate": 1572825600, "beta": 0.961, "volume": 5163, "regularMarketVolume": 5163, "averageVolume": 22307, "averageVolume10days": 29509, "averageDailyVolume10Day": 29509, "bid": 2.28, "ask": 2.37, "bidSize": 396000, "marketCap": 66268752, "fiftyTwoWeekLow": 1.16719, "fiftyTwoWeekHigh": 4.3, "priceToSalesTrailing12Months": 80.81555, "fiftyDayAverage": 2.8222332, "twoHundredDayAverage": 2.7897813, "currency": "USD", "enterpriseValue": 31503474, "floatShares": 24184721, "sharesOutstanding": 27961500, "heldPercentInsiders": 0.313, "heldPercentInstitutions": 0.05646, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -22560000, "enterpriseToRevenue": 38.419, "enterpriseToEbitda": -1.108, "exchange": "PNK", "quoteType": "EQUITY", "symbol": "MBGPF", "underlyingSymbol": "MBGPF", "shortName": "MOBERG PHARMA AB", "longName": "Moberg Pharma AB (publ)", "firstTradeDateEpochUtc": 1459949400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "1058cc14-09af-3f48-9680-aabf1b36a310", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.37, "recommendationKey": "none", "totalCash": 38631000, "totalCashPerShare": 1.382, "ebitda": -28436334, "totalDebt": 4425000, "quickRatio": 1.735, "currentRatio": 2.008, "totalRevenue": 820000, "debtToEquity": 0.732, "revenuePerShare": 0.04, "returnOnAssets": -0.030769998, "returnOnEquity": -0.03979, "freeCashflow": -123066752, "operatingCashflow": -31387000, "grossMargins": 0.6, "operatingMargins": -9.62927, "financialCurrency": "SEK", "trailingPegRatio": null, "__fetch_time": "2024-06-06"}]